Parallax Volatility Advisers’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-200
| Closed | -$38.8K | – | 2027 |
|
|
2024
Q3 | $38.8K | Buy |
+200
| New | +$41.8K | ﹤0.01% | 1851 |
|
|
2023
Q4 | – | Sell |
-27,300
| Closed | -$7.02M | – | 2183 |
|
|
2023
Q3 | $7.02M | Sell |
27,300
-9,300
| -25% | -$2.49M | 0.02% | 643 |
|
|
2023
Q2 | $10.4M | Buy |
+36,600
| New | +$10.9M | 0.02% | 519 |
|
|
2023
Q1 | – | Sell |
-34,000
| Closed | -$9.42M | – | 2729 |
|
|
2022
Q4 | $9.42M | Sell |
34,000
-28,000
| -45% | -$7.91M | 0.01% | 794 |
|
|
2022
Q3 | $16.6M | Buy |
62,000
+29,800
| +93% | +$6.33M | 0.03% | 572 |
|
|
2022
Q2 | $6.57M | Sell |
32,200
-17,000
| -35% | -$3.48M | 0.01% | 870 |
|
|
2022
Q1 | $10.4M | Buy |
+49,200
| New | +$10.7M | 0.01% | 735 |
|
|
2020
Q4 | – | Sell |
-46,000
| Closed | -$13M | – | 2446 |
|
|
2020
Q3 | $13M | Sell |
46,000
-4,200
| -8% | -$1.17M | 0.01% | 883 |
|
|
2020
Q2 | $13.4M | Buy |
50,200
+15,300
| +44% | +$4.6M | 0.02% | 654 |
|
|
2020
Q1 | $11M | Sell |
34,900
-68,500
| -66% | -$20.8M | 0.01% | 567 |
|
|
2019
Q4 | $30.7M | Sell |
103,400
-17,900
| -15% | -$4.97M | 0.04% | 314 |
|
|
2019
Q3 | $28.2M | Buy |
121,300
+20,700
| +21% | +$4.82M | 0.03% | 294 |
|
|
2019
Q2 | $23.5M | Buy |
100,600
+81,000
| +413% | +$18.7M | 0.03% | 312 |
|
|
2019
Q1 | $4.63M | Sell |
19,600
-84,400
| -81% | -$26.6M | 0.01% | 711 |
|
|
2018
Q4 | $31.3M | Buy |
104,000
+5,400
| +5% | +$1.72M | 0.04% | 264 |
|
|
2018
Q3 | $34.8M | Buy |
98,600
+32,100
| +48% | +$11.1M | 0.04% | 188 |
|
|
2018
Q2 | $19.3M | Buy |
66,500
+30,000
| +82% | +$8.43M | 0.03% | 280 |
|
|
2018
Q1 | $9.99M | Buy |
+36,500
| New | +$11.3M | 0.01% | 385 |
|
|
2017
Q3 | – | Sell |
-120,800
| Closed | -$32.8M | – | 2103 |
|
|
2017
Q2 | $32.8M | Buy |
120,800
+100,800
| +504% | +$26.7M | 0.06% | 176 |
|
|
2017
Q1 | $5.47M | Sell |
20,000
-55,000
| -73% | -$15.6M | 0.01% | 546 |
|
|
2016
Q4 | $21.3M | Buy |
75,000
+30,000
| +67% | +$8.89M | 0.04% | 258 |
|
|
2016
Q3 | $14.1M | Buy |
+45,000
| New | +$13.3M | 0.03% | 344 |
|
|
2016
Q2 | – | Sell |
-15,000
| Closed | -$3.9M | – | 2517 |
|
|
2016
Q1 | $3.9M | Hold |
15,000
| – | – | 0.01% | 654 |
|
|
2015
Q4 | $4.59M | Sell |
15,000
-55,000
| -79% | -$15.8M | 0.01% | 717 |
|
|
2015
Q3 | $20.4M | Buy |
+70,000
| New | +$23.1M | 0.05% | 263 |
|
|
2015
Q2 | – | Sell |
-60,500
| Closed | -$25.5M | – | 3617 |
|
|
2015
Q1 | $25.5M | Buy |
60,500
+60,200
| +20,067% | +$23.7M | 0.06% | 255 |
|
|
2014
Q4 | $102K | Hold |
300
| – | – | ﹤0.01% | 3443 |
|
|
2014
Q3 | $99K | Sell |
300
-5,700
| -95% | -$1.88M | ﹤0.01% | 2890 |
|
|
2014
Q2 | $1.89M | Sell |
6,000
-103,000
| -94% | -$31M | 0.01% | 799 |
|
|
2014
Q1 | $33.3M | Buy |
109,000
+33,700
| +45% | +$10.7M | 0.2% | 108 |
|
|
2013
Q4 | $21.1M | Buy |
75,300
+1,500
| +2% | +$388K | 0.1% | 177 |
|
|
2013
Q3 | $17.8M | Buy |
73,800
+14,300
| +24% | +$3.2M | 0.09% | 182 |
|
|
2013
Q2 | $12.8M | Buy |
+59,500
| New | +$12.7M | 0.06% | 237 |
|
Other funds holding BIIB
VCM
VPM
Parallax Volatility Advisers's BIIB Position: Q1 2026 in Review
Parallax Volatility Advisers reduced its Biogen (BIIB) stake by 24% in Q1 2026, selling an estimated $101K and leaving 1,689 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.
Parallax Volatility Advisers first reported a position in BIIB in Q4 2013 and has held it in 32 quarters since. The position peaked at $19.9M in Q1 2015. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Parallax Volatility Advisers held 1,689 shares of Biogen worth $314K as of Q1 2026.
- Parallax Volatility Advisers sold 548 Biogen shares in Q1 2026, an estimated $101K.
- Biogen made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q1 2026, its #1119 holding.
- Parallax Volatility Advisers first reported a position in Biogen in Q4 2013 and has held it in 32 quarters since.
- Parallax Volatility Advisers's Biogen position peaked at $19.9M in Q1 2015.
- 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.